Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has expanded its DMPK capabilities and expertise with the acquisition of XenoGesis, an independent laboratory-based CRO specializing in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.   This latest acquisition by Sygnature serves to meet both an increasing demand for its services and boost the company’s reach into the pre-clinical space.   This acquisition effectively d...